glp-1 weight watchers cost $350 → $245 → $149:

503A Compounding Pharmacies Limitations on Compounding Copies of Commercial Drugs The SAFE Drugs Act proposes to amend Section 503A of the FDCA to (i) codify the definition of essentially a copy of a commercially available drug product and (ii) prevent compounding pharmacies from compounding more than 20 units per month of any drug that is essentially a copy of a commercially available product unless tailored to an individual patient

While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that its worth investigating these weight-loss drugs as potential cancer prevention tools, McDonald said

[1] [3] Whilst these mechanisms contribute to improved glycaemic control and weight reduction, they also account for one of the most commonly reported adverse effects: nausea

The deal is expected to significantly expand access to GLP-1 drugs Wegovy and Zepbound for people in Medicare, many of whom will now get coverage to use the therapies specifically for weight loss

[DOI] [PubMed] [Google Scholar] 118.Degn K.B., Juhl C.B., Sturis J., et al

If a supplier claims to manufacture peptides but cannot provide facility registration numbers, inspection reports, or licensing verification, they are not actually manufacturing anything